Clinigen says trading in-line for current FY

11th Nov 2016 13:40

(ShareCast News) - Global pharmaceutical and services company Clinigen Group said its trading for the current financial year is in-line with directors' expectations.It said the year to 30 June marked the completion of its transformation into the global market leader in the management and supply of both unlicensed and clinical trial medicines."Alongside significant strategic progress, we delivered a strong financial performance with good levels of organic growth combining with acquisitions to increase adjusted EPS by 25%," said chairman Peter Allen in a statement."Trading for the current financial year remains in line with the board's expectations."Our focus is now fixed on leveraging our global leadership positions, and we will continue to drive organic growth supported by acquisitions and the revitalisation of products."Following the AIM-quoted company's annual meeting on Friday, Peter George stepped down as chief executive and was replaced by Shaun Chilton.At about 13:37 GMT, shares in Clinigen were down 0.97% to 717p.